Go for Wockhardt, Strides Arcolab: Abhishek Singhal
With the group of ministers meeting today to decide on the pharma pricing policy, everyone is watching the Finance Ministry’s stance of cost-plus pricing. Will the policy be slightly unfavourable to companies? Abhishek Singhal, associate director, Macquarie Capital Securities, talks about this important issue and goes on to list what he likes in terms of stocks.
